CRISPR Therapeutics appoints new R&D head

Gene-editing company CRISPR Therapeutics announced the appointment of Tony Ho as executive vice president and head of research & development.

Prior to joining CRISPR Therapeutics, Ho held a number of roles at AstraZeneca where he most recently was senior vice president and head of oncology integration and innovation.

Before AstraZeneca, Ho was the neurology and ophthalmology clinical section head at Merck Research Laboratories, Merck & Co., Inc. and led multiple development programs including the approval of Maxalt for pediatric migraine and Zioptan for glaucoma.

Earlier in his career, Ho was the co-founder and chief scientific officer of Neuronyx, Inc., a regenerative medicine company.

“I am excited to welcome Tony, who brings a wealth of experience and expertise to CRISPR Therapeutics,” said Rodger Novak, CEO of CRISPR Therapeutics.

“His leadership and proven track record of successfully shepherding therapeutics through development and approval will be instrumental as we continue to grow and advance our pipeline.”